**Core Concept**
The question is testing the knowledge of muscle relaxants suitable for patients with compromised liver and kidney function. In such cases, a drug with a low hepatic extraction ratio and minimal renal excretion is preferred to avoid accumulation and toxicity.

**Why the Correct Answer is Right**
Vecuronium, a non-depolarizing neuromuscular blocker, is the muscle relaxant of choice in hepatic and renal failure. Vecuronium is primarily metabolized by the liver, and its metabolites are excreted in the bile, which reduces the risk of accumulation in patients with renal failure. Additionally, vecuronium has a low hepatic extraction ratio, making it an ideal choice for patients with liver dysfunction.

**Why Each Wrong Option is Incorrect**
* **Option A:** Rocuronium is a non-depolarizing neuromuscular blocker with a higher hepatic extraction ratio compared to vecuronium. It is primarily metabolized by the liver and excreted in the bile, but its active metabolite, 17-desacetyl rocuronium, is excreted by the kidneys.
* **Option B:** Pancuronium is another non-depolarizing neuromuscular blocker, but it is primarily excreted by the kidneys. Its prolonged duration of action in renal failure makes it a less suitable choice.
* **Option C:** Succinylcholine is a depolarizing neuromuscular blocker that is primarily metabolized by plasma cholinesterase. However, its metabolites can accumulate in patients with renal failure, leading to prolonged neuromuscular blockade.

**Clinical Pearl / High-Yield Fact**
When selecting a muscle relaxant in patients with compromised liver and kidney function, consider drugs with low hepatic extraction ratios and minimal renal excretion.

**Correct Answer:** C. Pancuronium is not the correct answer, I assume the correct option is not provided, but according to the options available, we can say that the correct answer is not among the options.